ACT001 for Newly or Previously Treated Brain Stem Glioma
Part of Brain & nervous system, Cancer clinical trials.
This trial tests the drug ACT001 in people with a type of brain tumor called DIPG or other related high-grade gliomas. It aims to see if the drug can help control the tumor and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 1 and 39 years old.
- You have been diagnosed with DIPG or a related high-grade glioma.
- If newly diagnosed, you have completed radiation therapy within the last 28-35 days.
- If the tumor has come back or not responded to treatment, you must have had radiation as part of your prior treatment.
- You are well enough to carry out daily activities (performance score at least 50%).
- Your organ function (bone marrow, kidneys, liver, heart) is within normal limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two types of radiation therapy for children with diffuse intrinsic pontine glioma (DIPG), a rare brain tumor. It aims to see which treatment may be more effective while helping you understand your options.
This trial studies a targeted medicine approach for high-grade glioma (a fast-growing brain tumor) and some diffuse midline tumors, including DIPG. It may help by matching treatment to tumor biology using tumor testing done before or around starting standard therapy.
This trial tests a new drug called ACT001 for people with recurrent glioblastoma (a type of brain cancer) whose tumors have a specific marker (STAT3-high). The drug targets that marker to try to stop the tumor from growing.
This trial tests a combination of a vaccine made from tumor cells and a drug that may boost the immune system's ability to fight brain tumors. It is for children and young adults with a recurrent high-grade glioma or a newly diagnosed diffuse midline glioma with a specific genetic marker (H3K27M).
This early-phase trial tests a customized vaccine (made from your tumor’s cell parts) along with an immune “checkpoint blocker” medicine. It’s for newly diagnosed DIPG/DMG to see if this combination is safe and can help control the cancer.
This early-phase study tests CBL0137 in children and teens whose cancer has come back or is not responding to treatment. It is also for some specific hard-to-treat brain tumors, to see if the drug is safe and can work against the cancer.
Hear when a new Diffuse Intrinsic Pontine Gliomas (DIPG) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.